Atomwise vs Paige AI

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Atomwise employs 75 people, while Paige AI has 100-500 employees.

Atomwise has raised more in total funding at $219M, compared to Paige AI's $125M — a gap of $94M. Combined, the two companies have completed 5 known funding rounds.

Paige AI holds the higher Awaira Score at 65/100, compared to Atomwise's 53/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 12-point gap that reflects meaningful differences in scale or traction.

Atomwise was founded by Abraham Heifets in 2012. Paige AI was founded by Leo Grady in 2018. Visit each company's profile on Awaira for a full founder biography.

Atomwise: Atomwise is an artificial intelligence company focused on drug discovery and development, founded in 2012 and headquartered in the United States. The company uses AI and computational chemistry to identify and optimize potential drug candidates, reducing the time and cost associated with traditional pharmaceutical research methods. Atomwise's platform leverages machine learning algorithms to screen vast chemical libraries and predict molecular interactions, enabling faster identification of promising compounds for various therapeutic areas including oncology, infectious diseases, and genetic disorders. The company has secured $219 million in total funding and operates at the Series B stage, though its current valuation remains undisclosed. Atomwise's approach combines physics-based molecular modeling with machine learning to simulate how potential drugs interact with disease targets. The platform has been applied to multiple drug discovery projects across both internal programs and partnerships with pharmaceutical companies and research institutions. Atomwise competes in the growing computational drug discovery sector alongside companies utilizing AI for pharmaceutical development. The company's technology addresses significant pain points in drug development, including extended timelines and high failure rates. Its trajectory reflects the increasing adoption of AI-driven approaches in healthcare and pharmaceutical industries, positioning it within a broader trend toward computational acceleration of biomedical research and development processes. Atomwise applies physics-informed machine learning to molecular simulation for drug discovery, combining computational chemistry with AI to accelerate preclinical pharmaceutical development. Paige AI: Paige AI develops AI-powered pathology software that assists pathologists in identifying cancer and other diseases in digital whole-slide images. The platform received the first-ever FDA authorization for an AI-based primary diagnostic tool in pathology, a milestone that establishes regulatory precedent for clinical AI deployment in histopathology workflows.\n\nThe company raised approximately 125 million USD and partners with major academic medical centers and pathology laboratories to integrate its diagnostic AI into clinical workflows. Paige has expanded beyond prostate cancer detection into additional cancer types and is building a multi-cancer detection platform intended to function as a comprehensive AI layer across pathology departments.\n\nDigital pathology combined with AI represents one of the clearest near-term commercialization opportunities in medical AI, as the transition from glass slides to whole-slide imaging creates a digital substrate that AI can operate on at scale. Paige FDA clearance creates a significant regulatory moat that competitors must match before selling comparable diagnostic tools in the US market, giving the company a durable first-mover advantage in the AI-augmented pathology workflow.

Atomwise was founded first in 2012, giving it 6 years of additional market experience. Paige AI was founded later in 2018. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Atomwise has approximately 75 employees, while Paige AI has approximately 100-500. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Atomwise and Paige AI are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.